Objetivo Annually, about 13,000 women in the EU28 and 266,000 worldwide decease of cervical cancer caused by the human papilloma virus (HPV), thereby ranking third most common cancer worldwide . Throughout Europe, cervical screening programs are organized by local governments to detect cervical cancer at an early stage. Importantly, HPV-based screening (instead of cytology-based screening) is being implemented worldwide. However, a global challenge is that about 40% of women in the EU do not participate in these screening programs and are thus at-risk for development of cervical cancer. To reach these non-attendees, home self-sampling devices can increase the participation rate. The innovative Colli-PeeTM device developed by Novosanis offers a non-invasive, user-friendly solution. The device is suited for collection of first void urine (first 20ml of the urine flow) which allows for detection of HPV DNA. The Colli-PeeTM device thereby offers a novel innovative approach towards HPV-based screening.The VALPAS (VALidation of human PApilloma virus assays on Self-collected first void urine samples) project aims to successfully launch the Colli-Pee first void urine collection for HPV DNA testing in the EU28 and global market. The feasibility assessment in phase I aims to explore strategies with regard to market penetration & growth, competitors, pricing & reimbursement, partnerships, revenue models; ultimately leading to a business plan for Colli-PeeTM-based HPV screening. Specifically, phase I entails: - Market segment analysis- Competitor bench marking- Initiation of partnerships with diagnostic companies & labs- Exploration of pricing & reimbursement strategy- Assessment of diagnostic assays for analysis for HPV in urinePhase II funding will be requested to further validate the HPV assays for detection of HPV DNA in first void urine and set-up full scale production and exploitation strategy in the EU28 and at global level. Ámbito científico natural sciencesbiological sciencesmicrobiologyvirologynatural sciencesbiological sciencesgeneticsDNAsocial scienceseconomics and businessbusiness and managementbusiness modelsmedical and health sciencesclinical medicineoncologycervical cancermedical and health scienceshealth sciencesinfectious diseasesDNA viruses Programa(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Tema(s) PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Convocatoria de propuestas H2020-SMEInst-2014-2015 Consulte otros proyectos de esta convocatoria Convocatoria de subcontratación H2020-SMEINST-1-2015 Régimen de financiación SME-1 - SME instrument phase 1 Coordinador NOVOSANIS NV Aportación neta de la UEn € 50 000,00 Dirección BIJKHOEVELAAN 32C 2110 WIJNEGEM Bélgica Ver en el mapa Pyme Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención. Sí Región Vlaams Gewest Prov. Antwerpen Arr. Antwerpen Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 71 429,00
